Clinical trials: Head and Neck Tumours
Squamous Cell Carcinoma, Human Papilloma Virus (HPV)
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC).
- Conditions
- Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- Trial name
- NCT07513389
- Testing
- Active Surveillance With ctHPVDNA (NavDx®)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Upper Aerodigestive Tract Neoplasms, Lung Cancer
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment
This is a multicenter, interventional, randomized study among patients with a first lung or head \& neck cancer who are still active smokers ± alcohol misusers.The study will aim to compare the systematic implementation of an…
- Trial name
- ALTAKRA-1405 (NCT02540174)
- Testing
- integrated addiction treatment program, standard of care
- Where
- 3 sites in France
- Volunteers
- 133 people
- Sponsor
- Centre Oscar Lambret
Prostate Cancer, Bladder Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT00199849
- Testing
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Head and Neck Squamous Cell Carcinoma
Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study
Head and neck squamous cell carcinoma are frequent. The chemoradiotherapy protocols are part of the reference treatment of locally advanced stage tumors.
- Trial name
- ORODIFF (NCT02862678)
- Testing
- diffusion-weighted MRI
- Where
- France
- Volunteers
- 59 people
- Sponsor
- CHU de Reims
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
Brief Summary Study title: Indocyanine green (ICG)-guided omental shield anastomosis (ICG-OSA) technique for cervical esophagogastric anastomosis in esophageal cancer surgery Purpose: To evaluate whether a novel surgical…
- Trial name
- NCT07376876
- Testing
- Indocyanine green-guided omental shield anastomosis for cervical esophagogastric anastomosis
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Esophageal Squamous Cell Carcinoma
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC
- Trial name
- NCT01854749
- Testing
- S1 combined with cisplatin
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Fudan University
Thyroid Cancer
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Background: Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells.
- Trial name
- NCT06991738
- Testing
- 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Head and Neck Squamous Cell Carcinoma
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a randomized multicenter open label phase III factorial trial evaluating the 3 years OS in patients with locally advanced squamous cell carcinoma of head and neck treated with locoregional treatment (radiotherapy plus…
- Trial name
- H&N07 (NCT01086826)
- Testing
- RT+CDDP/5-FU, RT+CETUXIMAB, INDUCTION CTx(TPF)+(RT+CDDP/5-FU)
- Where
- 60 sites in Italy
- Volunteers
- 320 people
- Sponsor
- Associazione Volontari Pazienti Oncologici
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Head and Neck Neoplasms
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy.
- Trial name
- NCT01856478
- Testing
- Methotrexate, Afatinib
- Where
- 53 sites in China, Egypt and 6 more
- Volunteers
- 340 people
- Sponsor
- Boehringer Ingelheim
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Nasopharyngeal Neoplasms
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib as maintenace therapy for Nasopharyngeal Carcinoma With Metastasis after Chemoradiotherapy, including progress free survival(PFS)、overall survival (OS)、Quality of life…
- Trial name
- NCT03180476
- Testing
- Apatinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Oral Cancer, Oral Premalignant Lesion
Innovative Approach to Triage Oral Precancer
Oral cancer is a major health problem worldwide, accounting for 274,000 new cases and 145,000 deaths annually. On average, half of the patients die within 5 years of an oral cancer diagnosis.
- Trial name
- iTOP (NCT03202810)
- Where
- Canada
- Volunteers
- 360 people
- Sponsor
- British Columbia Cancer Agency
Lung Cancer, Esophageal Cancer
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using…
- Conditions
- Lung Cancer, Esophageal Cancer, Mesothelioma; Lung
- Trial name
- NCT04804410
- Testing
- LCR Meter (Brand: Keysight, Serial Number:E498AL)
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma
- Trial name
- NCT02538510
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Squamous Cell Carcinoma of the Head and Neck
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than…
- Trial name
- NCT03349710
- Testing
- Nivolumab, Cetuximab, Cisplatin
- Where
- 55 sites in United States, France and 8 more
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Melanoma, Non-small Cell Lung Cancer
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05117138
- Testing
- AMT-116 CAR-T cells, AMT-253 CAR-T cells
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.